Cargando…

JAK2 Exon 14 Skipping in Patients with Primary Myelofibrosis: A Minor Splice Variant Modulated by the JAK2-V617F Allele Burden

BACKGROUND: Primary myelofibrosis (PMF) is an acquired clonal disease of the hematopoietic stem cell compartment, characterized by bone marrow fibrosis, anemia, splenomegaly and extramedullary hematopoiesis. About 60% of patients with PMF harbor a somatic mutation of the JAK2 gene (JAK2-V617F) in th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Catarsi, Paolo, Rosti, Vittorio, Morreale, Giacomo, Poletto, Valentina, Villani, Laura, Bertorelli, Roberto, Pedrazzini, Matteo, Zorzetto, Michele, Barosi, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4305294/ https://www.ncbi.nlm.nih.gov/pubmed/25617626 http://dx.doi.org/10.1371/journal.pone.0116636

Ejemplares similares

JAK2 V617F Genotype Is a Strong Determinant of Blast Transformation in Primary Myelofibrosis
por: Barosi, Giovanni, et al.
Publicado: (2013)

Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression
por: Malara, Alessandro, et al.
Publicado: (2022)

Evidence that Prefibrotic Myelofibrosis Is Aligned along a Clinical and Biological Continuum Featuring Primary Myelofibrosis
por: Barosi, Giovanni, et al.
Publicado: (2012)

Loss of wild-type Jak2 allele enhances myeloid cell expansion and accelerates myelofibrosis in Jak2V617F knock-in mice
por: Akada, Hajime, et al.
Publicado: (2014)

Constitutive STAT5 phosphorylation in CD34(+) cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity
por: Abbà, Carlotta, et al.
Publicado: (2019)

Clinical Relevance of VEGFA (rs3025039) +936 C>T Polymorphism in Primary Myelofibrosis: Susceptibility, Clinical Co-Variates, and Outcomes
por: Villani, Laura, et al.
Publicado: (2021)

Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis
por: Campanelli, Rita, et al.
Publicado: (2016)

Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera
por: Liu, Dan, et al.
Publicado: (2021)

VEGFA rs3025020 Polymorphism Contributes to CALR -Mutation Susceptibility and Is Associated with Low Risk of Deep Vein Thrombosis in Primary Myelofibrosis
por: Villani, Laura, et al.
Publicado: (2021)

Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score
por: Barbui, Tiziano, et al.
Publicado: (2022)

VEGFA rs3025039 is associated with phenotype severity of myelofibrosis‐type megakaryocyte dysplasia
por: Barosi, Giovanni, et al.
Publicado: (2023)

The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
por: Ikeda, Kazuhiko, et al.
Publicado: (2017)

JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden
por: Ferdowsi, Shirin, et al.
Publicado: (2016)

Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in Essential Thrombocythemia and Myelofibrosis
por: Tognon, Raquel, et al.
Publicado: (2012)

New Markers of Disease Progression in Myelofibrosis
por: Campanelli, Rita, et al.
Publicado: (2021)

ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden
por: Wang, Yu-Hung, et al.
Publicado: (2020)

PB2178: EVALUATION OF JAK2 EXON 12 MUTATIONS IN PATIENTS WITH JAK2 (V617F)-NEGATIVE POLYCYTHEMIA VERA
por: Khosravi, Sahar, et al.
Publicado: (2023)

P982: MYELOID-DERIVED SUPPRESSOR CELLS: CHARACTERIZATION IN PERIPHERAL BLOOD AND SPLEEN TISSUE OF PATIENTS WITH MYELOFIBROSIS
por: Campanelli, R., et al.
Publicado: (2022)

Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms
por: Yonal-Hindilerden, Ipek, et al.
Publicado: (2015)

Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden
por: Lee, A-Jin, et al.
Publicado: (2021)

Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis
por: Barosi, Giovanni, et al.
Publicado: (2015)

JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis
por: Kim, Bo Hyun, et al.
Publicado: (2015)

Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis
por: Shimizu, Takafumi, et al.
Publicado: (2016)

Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis
por: Yönal, İpek, et al.
Publicado: (2016)

JAK2(V617F) allele burden in polycythemia vera: burden of proof
por: Moliterno, Alison R., et al.
Publicado: (2023)

Treatment and management of myelofibrosis in the era of JAK inhibitors
por: Keohane, Clodagh, et al.
Publicado: (2013)

Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis
por: Nakaya, Y, et al.
Publicado: (2014)

Inhibition of Osteoblast Differentiation by JAK2(V617F) Megakaryocytes Derived From Male Mice With Primary Myelofibrosis
por: Karagianni, Aikaterini, et al.
Publicado: (2022)

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
por: Pardanani, A, et al.
Publicado: (2013)

The Burden of JAK2V617F Mutated Allele in Turkish Patients With Myeloproliferative Neoplasms
por: Yonal-Hindilerden, Ipek, et al.
Publicado: (2015)

Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations
por: Lee, Tai-Sung, et al.
Publicado: (2009)

Immunoproteasome Genes Are Modulated in CD34(+) JAK2(V617F) Mutated Cells from Primary Myelofibrosis Patients
por: Di Rosa, Michelino, et al.
Publicado: (2020)

Inhibition of interleukin-1β reduces myelofibrosis and osteosclerosis in mice with JAK2-V617F driven myeloproliferative neoplasm
por: Rai, Shivam, et al.
Publicado: (2022)

PB2192: JAK2 V617F ALLELE BURDEN AND THROMBOTIC EVENTS IN PATIENTS WITH JAK2 V617F POSITIVE POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA AT HIGH RISK OF THROMBOSIS
por: Hwang, Yun Hui, et al.
Publicado: (2023)

Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]
Publicado: (2013)

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
por: Bose, Prithviraj, et al.
Publicado: (2020)

Myelofibrosis in 2019: moving beyond JAK2 inhibition
por: Schieber, Michael, et al.
Publicado: (2019)

Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms. Challenges and perspectives
por: Barosi, Giovanni, et al.
Publicado: (2023)

JAK2V617F-Positive Endothelial Cells Induce Apoptosis and Release JAK2V617F-Positive Microparticles
por: Hekimoğlu, Hilal, et al.
Publicado: (2022)

Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative Neoplasms
por: Yönal-Hindilerden, İpek, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h9kipr9pflscdj8m1m9gkc3c0s